To date, in lymphoma this approach has been exploited through the use of endostatin, an endogenous inhibitor of angiogenesis which inhibits matrix metalloproteinases (MMP) activity and blocks VEGF binding to VEGFR-2. Here, COL18A1 is linked to lymphoma.